EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Leukotriene-modifying agent chemoprophylaxis for severe influenza illness: a multi-approach study

Brittney M Snyder, Corinne A Riddell iD, Tebeb Gebretsadik, Tan Ding, Rees L Lee, William D Dupont, Justin R Ortiz iD, Veronika Pav, Thomas J Braciale, Pingsheng Wu iD, Tina V Hartert iD

American Journal of Epidemiology · 03.06.2026 · 195 (6) · 1634-1646

DOI: 10.1093/aje/kwag072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Epidemiology, online erschienen am 01.04.2026. Verfasst von Brittney M Snyder und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN, United States. Hauptthemen laut MEDLINE: Influenza, Human, Leukotriene Antagonists, Acetates, Quinolines. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Animal and in vitro studies suggest that leukotriene-modifying agents (LMAs) may decrease susceptibility to influenza illness. We estimated the effect of LMAs on severe human influenza illness in a retrospective cohort using three analytic approaches: (1) a marginal structural model, (2) a proportional hazards model, and (3) a case–time–control design. Study populations included individuals with asthma and/or allergic rhinitis for whom LMAs are approved and who were enrolled in Tennessee Medicaid (TennCare) or Department of Defense Military Health System (DoD MHS) from 1995 to 2019. Exposed periods were defined by LMA prescription start dates plus days' supply. Severe influenza illness was defined using previously validated International Classification of Diseases criteria. Montelukast accounted for 99% of LMA prescription fills. Adjusted incidence rate ratios from the marginal structural model and adjusted hazard ratios from the proportional hazards model were 1.26 (95% confidence interval [CI], 0.99-1.59) and 1.14 (95% CI, 0.92-1.41) for TennCare and 1.01 (95% CI, 0.84-1.21) and 0.97 (95% CI, 0.82-1.16) for DoD MHS, respectively. Adjusted odds ratios from the case–time–control were 1.11 (95% CI, 0.74-1.65) for TennCare and 1.91 (95% CI, 1.29-2.84) for DoD MHS. Findings in different populations and designs do not support the use of LMAs for chemoprophylaxis of severe influenza illness. Conclusions regarding LMAs other than montelukast were not possible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanLeukotriene AntagonistsAcetatesQuinolinesHumansRetrospective StudiesFemaleCyclopropanesMaleAdultProportional Hazards ModelsSulfidesUnited StatesCase-Control StudiesMiddle AgedAsthmaTennesseeChemopreventionYoung AdultAdolescent

Stichwörter der Autor:innen

case–time–controlchemoprophylaxisleukotriene-modifying agentsmarginal structural modelpandemic preparednessproportional hazardssevere influenza illness

Substanzen

Leukotriene AntagonistsAcetatesCyclopropanesQuinolinesmontelukastSulfides

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN, United States.
  • Divisions of Biostatistics and Epidemiology, School of Public Health, University of California, Berkeley, CA, United States.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States.
  • Department of Pediatrics, University of Arizona, College of Medicine, Tucson, AZ, United States.
  • Center for Vaccine Development & Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
  • Kennell and Associates Inc., Falls Church, VA, United States.

ORCID-Profile: Corinne A Riddell, Justin R Ortiz, Pingsheng Wu, Tina V Hartert

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Snyder, B. M., Riddell, C. A., Gebretsadik, T., Ding, T., Lee, R. L., Dupont, W. D., Ortiz, J. R., Pav, V., Braciale, T. J., Wu, P., & Hartert, T. V. (2026). Leukotriene-modifying agent chemoprophylaxis for severe influenza illness: a multi-approach study. American Journal of Epidemiology, 195(6), 1634-1646. https://doi.org/10.1093/aje/kwag072

Vancouver

Snyder BM, Riddell CA, Gebretsadik T, Ding T, Lee RL, Dupont WD, et al. Leukotriene-modifying agent chemoprophylaxis for severe influenza illness: a multi-approach study. American Journal of Epidemiology. 2026;195(6):1634-1646. doi:10.1093/aje/kwag072

BibTeX
@article{Snyder2026,
  author = {Snyder, Brittney M and Riddell, Corinne A and Gebretsadik, Tebeb and Ding, Tan and Lee, Rees L and Dupont, William D and Ortiz, Justin R and Pav, Veronika and Braciale, Thomas J and Wu, Pingsheng and Hartert, Tina V},
  title = {Leukotriene-modifying agent chemoprophylaxis for severe influenza illness: a multi-approach study},
  journal = {American Journal of Epidemiology},
  year = {2026},
  volume = {195},
  number = {6},
  pages = {1634--1646},
  doi = {10.1093/aje/kwag072}
}
Kostenlos starten →